0001209191-20-004301.txt : 20200121 0001209191-20-004301.hdr.sgml : 20200121 20200121172301 ACCESSION NUMBER: 0001209191-20-004301 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200116 FILED AS OF DATE: 20200121 DATE AS OF CHANGE: 20200121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Currie Mark G CENTRAL INDEX KEY: 0001478244 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34620 FILM NUMBER: 20537074 MAIL ADDRESS: STREET 1: C/O CYCLERION THERAPEUTICS, INC. STREET 2: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001446847 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043404176 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-16 0 0001446847 IRONWOOD PHARMACEUTICALS INC IRWD 0001478244 Currie Mark G C/O IRONWOOD PHARMACEUTICALS, INC. 100 SUMMER STREET, SUITE 2300 BOSTON MA 02110 1 0 0 0 Class A Common Stock 2020-01-16 4 M 0 8888 10.02 A 558160 D Class A Common Stock 2020-01-16 4 S 0 8888 12.80 D 549272 D Employee Stock Option (Right to Buy) 10.02 2020-01-16 4 M 0 8888 0.00 D 2020-02-02 Class A Common Stock 8888 0 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.74 to $12.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This option, granted as an annual performance award, is presently exercisable in full. /s/ Conor Kilroy, Attorney-in-Fact 2020-01-21